Fellows will receive a competitive stipend and benefit package, including comprehensive health insurance
Employer will assist with relocation costs.
Novartis Institutes for BioMedical Research (NIBR), in collaboration with MCPHS, offers a unique fellowship program to promote the role of the Doctor of Pharmacy (PharmD) within the biopharmaceutical industry. A fellow gains extensive experiences through various practical activities in both industry and academic settings, which could enhance the potential for accelerated career development.
Novartis Oncology and NIBR collaborate to form TCO; our group accelerates innovative hematology/oncology compounds from target discovery to commercialization. TCO aims to advance patient outcomes in early trials by selecting patients based on the molecular mechanism of drugs and diseases.
The TCO function is responsible for: developing the strategy and executing first-in-human and proof-of-concept clinical trials for hematology/oncology therapeutics using adaptive design; developing and executing biomarker and imaging strategies in clinical trials; providing robust research support to hematology/oncology compounds to increase clinical trial success and maximize patient benefit through patient stratification, indication expansion, and combination therapy; managing of global clinical trials using patient selection and targeted therapies; and ensuring a smooth hand-off to full development to advance medicines to market.
Our fellow will learn to: • Lead and participate in the clinical trial team to impact study design, conduct, and analysis • Lead and coordinate the development of clinical trial protocols, amendments and related documents; drive and/or contribute to the development of trial-related documents and processes • Develop effective working relationships with investigators. Support protocol training meetings and support CPOs in regulatory submission preparation and the conduct of regional meetings. • Support the global multidisciplinary CTT to ensure all trial deliverables are met according to timelines, budget, quality standards and operational procedures: attend CTT meetings, assist in report study progress and issues. • Prepare dose escalation meetings with investigators. Coordinate the real time availability of quality clinical trial data, including safety, efficacy, pharmacokinetic, imaging and biomarker data, to provide consolidated information for dose escalation meetings with investigators. • Contribute to the design of data capture tools and statistical analysis plans • Create and obtain essential regulatory trial documents • Orchestrate selection and oversight of clinical trial sites and external vendors • Participate in the ongoing review and cleaning of the clinical trial data, support final analysis and interpretation including the development of clinical trial reports, publications and internal/external presentations. • Contribute to development of clinical section of regulatory documents like Investigator’s Brochure, safety updates, IND/NDA submission documents, responses to Health Authorities questions
To be considered for an interview, please complete a fellowship application on the MCPHS SMApply application portal. Visit https://mcphs.smapply.io/
Please DO NOT request an interview within PPS. Our recruitment teams will contact qualified candidates via email to schedule interviews.
The MCPHS application portal will open up on October 3, 2022. Applicants must upload the following application materials to the online portal by November 11, 2022:
Letter of intent
Unofficial college transcript
Contact information for three references. References will receive an electronic recommendation form to complete separately.
Incomplete applications WILL NOT be reviewed. Interviews CANNOT be scheduled until these materials have been submitted. Please keep in mind that this is a competitive process and applicants are encouraged to complete their applications as soon as possible.
Three recommendation evaluation forms must be submitted no later than December 1, 2022, via the online portal. This is NOT a letter of recommendation but an online form that the reference will need to complete.
Rolling Application Review & Interviews
All submitted applications will be reviewed on a rolling basis. Interviews will also be offered on a rolling basis and opportunities are limited. Priority will be given to those applicants who apply early, well in advance of the deadline.
Rolling interviews will begin mid-October with pre-screens and a mixture of interview rounds, and will conclude in December at the end of the ASHP Midyear Clinical Meeting. Candidates will be notified if selected for an interview.
ASHP Midyear & Onsite Interviews
The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in Las Vegas. Applicants are strongly encouraged to attend. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details.
Top candidates may be invited for interviews at the sponsoring company’s location pending COVID – 19 restrictions.
Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, MCPHS in conjunction with the Academic Industry Fellowship Alliance (AIFA), has agreed to extend offers for Fellowships no earlier than December 7, 2022.
Final candidates will be required to go through additional screening / onboarding as required by MCPHS.
The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis. Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.
Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
All candidates must have authorization to work in the United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).
About Novartis Institutes for BioMedical Research (NIBR) & MCPHS University
The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. We collaborate across scientific and organizational boundaries, with a focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients.
The Novartis global clinical pipeline includes more than 200 projects and over 500 clinical trials. Within NIBR, we have more than 5,600 dedicated scientists and physicians, working across 6 global campuses.